X
Details:
Through the acquisition, Juvise Pharmaceuticals will leverage its expertise to commercialize and develop Ponvory(ponesimod), a first-line treatment option in active forms of relapsing multiple sclerosis, outside of the United States and Canada, with a focus on Europe.
Lead Product(s): Ponesimod
Therapeutic Area: Neurology Product Name: Ponvory
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Actelion Pharmaceuticals Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 26, 2024
Details:
Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.
Lead Product(s): Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Pylera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 05, 2022
Details:
Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
Lead Product(s): Anastrozole
Therapeutic Area: Oncology Product Name: Arimidex
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Manufactures & Commercializes medicines in therapeutic areas like Oncology, Cardiology, & Neurology-psychiatry.
